Other substances

Losartan

A non-peptide angiotensin II antagonist.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Losartan on PubChem

Marketed as

COZAAR; LORTAAN; LOSARTAN; LOSARTAN POTASSIUM

CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.	Theory only		Angiotensin receptor 1 (AT1R) blocker - angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2	Mar/04/2020

AI-suggested references

Link	Publication date
Randomized Placebo-Controlled Trial of Losartan for Pediatric Nonalcoholic Fatty Liver Disease.	Feb/28/2022
Losartan Inhibits SARS-CoV-2 Replication in Vitro.	Oct/22/2021
Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells.	Sep/01/2021
Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex	Oct/07/2021
ACE2 as a potential therapeutic target for pandemic COVID-19	Nov/01/2020
Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells	Nov/19/2021
Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury	Sep/19/2020
A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19	Jun/17/2021
Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids	May/21/2020
Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19	May/01/2020
Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia	May/11/2021
Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: A feasibility study	Dec/30/2020
Oral Lisinopril Raises Tissue Levels of ACE2, the SARS-CoV-2 Receptor, in Healthy Male and Female Mice	Sep/11/2021
A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice	Nov/02/2021
An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19	Jan/10/2022
Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial	Mar/13/2021
Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study	Nov/08/2021
Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease	Jun/29/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04328012	COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19	Recruiting	Phase 2\|Phase 3	Apr/06/2020	Aug/01/2021
Alternative id - 1581969 Interventions - Drug: Losartan\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Bassett Medical Center, Cooperstown, New York, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)\|Hospital length of stay (LOS)\|Intensive care unit level LOS\|Mechanical ventilation\|survival
NCT04312009	Losartan for Patients With COVID-19 Requiring Hospitalization	Completed	Phase 2	Apr/13/2020	Feb/01/2021
Alternative id - SURG-2020-28675\|INV-017069 Interventions - Drug: Losartan\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - University of Florida Health Gainesville, Gainesville, Florida, United States\|University of Florida Health Jacksonville, Jacksonville, Florida, United States\|Grady Memorial Hospital, Atlanta, Georgia, United States\|Henry Ford Hospital, Detroit, Michigan, United States\|M Health Fairview Ridges Hospital, Burnsville, Minnesota, United States\|M Health Fairview Southdale Hospital, Edina, Minnesota, United States\|Hennepin County Medical Center, Minneapolis, Minnesota, United States\|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States\|University of Minnesota, Minneapolis, Minnesota, United States\|North Memorial Health Hospital, Robbinsdale, Minnesota, United States\|University of Mississippi Medical Center, Jackson, Mississippi, United States\|Cooper University Hospital, Camden, New Jersey, United States\|University of Cincinnati Medical Center, Cincinnati, Ohio, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 205 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days\|Daily Hypotensive Episodes\|Hypotension Requiring Vasopressors\|Acute Kidney Injury\|Sequential Organ Failure Assessment (SOFA) Total Score\|Oxygen Saturation / Fractional Inhaled Oxygen (S/F)\|28-Day Mortality\|90-Day Mortality\|ICU Admission\|Number of Ventilator-Free Days\|Number of Therapeutic Oxygen-Free Days\|Number of Vasopressor-Free Days\|Length of ICU Stay\|Length of Hospital Stay\|Incidence of Respiratory Failure\|Change in PROMIS Dyspnea scale\|Change in SF-12 Physical Composite Score\|Change in SF-12 Mental Composite Score\|Disease Severity Rating\|Viral Load by Nasopharyngeal Swab Day 9\|Viral Load by Nasopharyngeal Swab Day 15\|Viral Load by Blood Day 9\|Viral Load by Blood Day 15
NCT04349410	The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol	Completed	Phase 2\|Phase 3	Apr/11/2020	Sep/14/2020
Alternative id - FMTVDM2020 Interventions - Drug: Hydroxychloroquine, Azithromycin\|Drug: Hydroxychloroquine, Doxycycline\|Drug: Hydroxychloroquine, Clindamycin\|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.\|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.\|Drug: Remdesivir\|Drug: Tocilizumab\|Drug: Methylprednisolone\|Drug: Interferon-Alpha2B\|Drug: Losartan\|Drug: Convalescent Serum Study type - Interventional Study results - No Results Available Locations - FHHI-OI-Camelot; QME, Los Angeles, California, United States Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: Single (Investigator)\|Primary Purpose: Treatment Enrollment - 1800 Age - Child, Adult, Older Adult Outcome measures - Improvement in FMTVDM Measurement with nuclear imaging.\|Ventilator status\|Survival status
NCT04428268	Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia	Withdrawn	Phase 2	Mar/10/2020	Feb/16/2021
Alternative id - IF20-00003 Interventions - Drug: Chloroquine Phosphate Tablets Study type - Interventional Study results - No Results Available Locations - Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Overall mortality\|Clinical outcome assessment\|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0\|Time to negative SARS-CoV-2 test
NCT04447235	Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection	Recruiting	Phase 2	Jul/23/2020	Feb/01/2021
Alternative id - NP 1677/20 Interventions - Drug: Placebo\|Drug: Ivermectin\|Drug: Losartan Study type - Interventional Study results - No Results Available Locations - Instituto do Cancer do Estado de Sao Paulo, SAo Paulo, Brazil Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Care Provider)\|Primary Purpose: Treatment Enrollment - 176 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Incidence of severe complications due COVID-19 infection\|Incidence of Severe Acute Respiratory Syndrome\|Adverse events\|Overall survival
NCT04643691	Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS	Recruiting	Phase 2	Sep/11/2020	Oct/30/2022
Alternative id - 2020-24\|2020-001766-11 Interventions - Drug: Losartan 50 mg and Spironolactone 25 mg pillules oral use Study type - Interventional Study results - No Results Available Locations - Assistance Publique Hôpitaux de Marseille, Marseille, France Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 90 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - SOFA score\|Pa02/Fi02\|Duration of mechanical ventilation\|Death
NCT04340557	Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection	Completed	Phase 4	Mar/27/2020	Jun/13/2020
Alternative id - COVID-ARB\|2003902 Interventions - Drug: Losartan Study type - Interventional Study results - Has Results Locations - Sharp Grossmont Hospital, La Mesa, California, United States\|Sharp Chula Vista Medical Center, San Diego, California, United States\|Sharp Memorial Hospital, San Diego, California, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 31 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Mechanical Ventilation\|ICU Transfer\|Oxygen Therapy
NCT04335123	Study of Open Label Losartan in COVID-19	Completed	Phase 1	Apr/04/2020	Aug/17/2020
Alternative id - STUDY00145514 Interventions - Drug: Losartan Study type - Interventional Study results - No Results Available Locations - University of Kansas Medical Center, Kansas City, Kansas, United States Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 34 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Number of participants with treatment-related adverse events as assessed by protocol definition of AE\|Number of days on supplemental oxygen in respiratory failure due to COVID-19\|Incidence of mechanical ventilation use\|Days on mechanical ventilation\|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use\|Days on non-invasive positive pressure ventilation or high flow nasal cannula\|Incidence of transfer to ICU from non-ICU hospital bed\|ICU length of stay (days)\|30-day mortality rate\|Hospital length of stay (days)\|Cumulative incidence of severe adverse events\|Cumulative incidence of adverse events\|Change from baseline in oxygenation\|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)\|Incidence (and length in days) of extracorporeal membrane oxygenation use\|Incidence (and length in days) of renal replacement therapy use\|Intolerance of high dose (50mg) losartan after tolerating 25mg
NCT04343001	Coronavirus Response - Active Support for Hospitalised Covid-19 Patients	Withdrawn	Phase 3	Oct/01/2020	Aug/01/2021
Alternative id - 2020-KEP-420 Interventions - Drug: Aspirin\|Drug: Losartan\|Drug: Simvastatin Study type - Interventional Study results - No Results Available Locations - University College Hospital, Ibadan, Oyo, Nigeria\|Shifa Tameer-e-Millat University, Rawalpindi, Pakistan Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 0 Age - 40 Years and older (Adult, Older Adult) Outcome measures - Death\|Myocardial infarction\|Congestive cardiac failure\|Severe cardiac arrythmia\|Myocarditis\|Respiratory failure including ARDS\|Viral pneumonitis\|Acute renal failure\|Sepsis\|Stroke\|Gastrointestinal bleeding\|Receipt of non invasive or mechanical ventilation\|Ability to self care at hospital discharge
NCT04311177	Losartan for Patients With COVID-19 Not Requiring Hospitalization	Completed	Phase 2	Apr/09/2020	Feb/01/2021
Alternative id - SURG-2020-28683 Interventions - Drug: Losartan\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - Hennepin County Medical Center, Minneapolis, Minnesota, United States\|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States\|University of Minnesota, Minneapolis, Minnesota, United States\|Mayo Clinic Health System, Rochester, Minnesota, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 162 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Hospital Admission\|Change in PROMIS Dyspnea scale\|Change in SF-12 Physical Composite Score\|Change in SF-12 Mental Composite Score\|Daily Maximum Temperature\|Emergency Department/Clinic Presentations\|Disease Severity Rating Day 7\|Disease Severity Rating Day 15\|Disease Severity Rating Day 28\|Viral Load by Oropharyngeal Swab Day 9\|Viral Load by Oropharyngeal Swab Day 15\|Ventilator-Free Days\|Therapeutic Oxygen-Free Days\|Need for Hospital Admission at 15 Days\|Need for Oxygen Therapy at 15 Days
NCT04606563	Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?	Recruiting	Phase 3	Oct/09/2020	Jun/30/2021
Alternative id - H20-01984 Interventions - Drug: Losartan Study type - Interventional Study results - No Results Available Locations - University of Nebraska, Omaha, Nebraska, United States\|Brown University, Providence, Rhode Island, United States\|Vanderbilt University, Nashville, Tennessee, United States\|St. Luc University Hospital, Brussels, Belgium\|Clinique Saint-Pierre, Ottignies, Belgium\|University of Calgary - Foothills, Calgary, Alberta, Canada\|Royal Columbian Hospital, New Westminster, British Columbia, Canada\|Surrey Memorial Hospital, Surrey, British Columbia, Canada\|St Paul's Hospital, Vancouver, British Columbia, Canada\|Vancouver General Hospital, Vancouver, British Columbia, Canada\|Queens University, Kingston, Ontario, Canada\|The Ottawa Hospital, Ottawa, Ontario, Canada\|St Michael's Hospital, Toronto, Ontario, Canada\|Sunnybrook Hospital, Toronto, Ontario, Canada\|McGill University Health Center, Montréal, Quebec, Canada\|Université de Sherbrooke, Sherbrooke, Quebec, Canada\|Centre Hospitalier Universitaire d'Angers, Angers, France\|Chiba University, Chiba, Japan\|Hospital Clínico San Carlos, Madrid, Spain Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 1372 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Mortality\|Hospital Mortality\|ICU Admission\|days alive and free of vasopressors, ventilation, and renal replacement therapy\|SOFA score\|Acute cardiac injury\|Severe adverse events

Export (.csv)